1314 Trilaciclib, an intravenous cyclin-dependent kinase 4/6 inhibitor, enhances antitumor responses by modulating T cells

Abstract

BackgroundCyclin-dependent kinase (CDK)4/6 inhibitors, including trilaciclib, have been shown to augment antitumor immunity.1,2 In an open-label, phase 2 trial in patients with metastatic triple-negative breast cancer (mTNBC), administration of trilaciclib...